http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 04 Jun 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SciSparc+Ltd.+++++++++++++For%3A+Jun+04/26602698.html si-local-file:///var/storage/secattach/20260604/26602698.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SciSparc+Ltd.+++++++++++++For%3A+Jun+04/26602698.html Thu, 04 Jun 2026 08:00:00 -0400 O.06196855 SPRC http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SciSparc+Ltd.+++++++++++++For%3A+Jun+04/26602698.html si-local-file:///var/storage/secattach/20260604/26602698.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SciSparc+Ltd.+++++++++++++For%3A+Jun+04/26602698.html Thu, 04 Jun 2026 08:00:00 -0400 O.06196855 SPRC http://www.streetinsider.com/Mergers+and+Acquisitions/NeuroThera+Labs+acquires+54%25+stake+in+CliniQuantum+for+CAD%249.5+million/26602471.html <p>SciSparc Ltd. (NASDAQ: SPRC) announced that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) completed the acquisition of approximately 54% of CliniQuantum Ltd., a private Israeli technology company.</p> <p>NeuroThera acquired 56,375 ordinary shares of CliniQuantum in exchange for 56,600,000 common shares valued at approximately CAD$9,459,954.20, based on NeuroThera's 20-day volume weighted average trading price on the TSX Venture Exchange as of the share purchase agreement date.</p> <p>The transaction includes potential earn-out payments of up to $2,500,000 over three years. These payments consist of $500,000 for each of the first three patent applications filed regarding the licensed technology, up to $1,500,000 total, and 7% http://www.streetinsider.com/Mergers+and+Acquisitions/NeuroThera+Labs+acquires+54%25+stake+in+CliniQuantum+for+CAD%249.5+million/26602471.html Thu, 04 Jun 2026 07:32:19 -0400 A.36078215 O.02555813 O.06196855 SPRC http://www.streetinsider.com/Mergers+and+Acquisitions/NeuroThera+Labs+acquires+54%25+stake+in+CliniQuantum+for+CAD%249.5+million/26602471.html <p>SciSparc Ltd. (NASDAQ: SPRC) announced that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) completed the acquisition of approximately 54% of CliniQuantum Ltd., a private Israeli technology company.</p> <p>NeuroThera acquired 56,375 ordinary shares of CliniQuantum in exchange for 56,600,000 common shares valued at approximately CAD$9,459,954.20, based on NeuroThera's 20-day volume weighted average trading price on the TSX Venture Exchange as of the share purchase agreement date.</p> <p>The transaction includes potential earn-out payments of up to $2,500,000 over three years. These payments consist of $500,000 for each of the first three patent applications filed regarding the licensed technology, up to $1,500,000 total, and 7% http://www.streetinsider.com/Mergers+and+Acquisitions/NeuroThera+Labs+acquires+54%25+stake+in+CliniQuantum+for+CAD%249.5+million/26602471.html Thu, 04 Jun 2026 07:32:19 -0400 A.36078215 O.02555813 O.06196855 SPRC http://www.streetinsider.com/Mergers+and+Acquisitions/NeuroThera+Labs+acquires+54%25+stake+in+CliniQuantum+for+CAD%249.5+million/26602471.html <p>SciSparc Ltd. (NASDAQ: SPRC) announced that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) completed the acquisition of approximately 54% of CliniQuantum Ltd., a private Israeli technology company.</p> <p>NeuroThera acquired 56,375 ordinary shares of CliniQuantum in exchange for 56,600,000 common shares valued at approximately CAD$9,459,954.20, based on NeuroThera's 20-day volume weighted average trading price on the TSX Venture Exchange as of the share purchase agreement date.</p> <p>The transaction includes potential earn-out payments of up to $2,500,000 over three years. These payments consist of $500,000 for each of the first three patent applications filed regarding the licensed technology, up to $1,500,000 total, and 7% http://www.streetinsider.com/Mergers+and+Acquisitions/NeuroThera+Labs+acquires+54%25+stake+in+CliniQuantum+for+CAD%249.5+million/26602471.html Thu, 04 Jun 2026 07:32:19 -0400 A.36078215 O.02555813 O.06196855 SPRC http://www.streetinsider.com/Mergers+and+Acquisitions/NeuroThera+Labs+acquires+54%25+stake+in+CliniQuantum+for+CAD%249.5+million/26602471.html <p>SciSparc Ltd. (NASDAQ: SPRC) announced that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) completed the acquisition of approximately 54% of CliniQuantum Ltd., a private Israeli technology company.</p> <p>NeuroThera acquired 56,375 ordinary shares of CliniQuantum in exchange for 56,600,000 common shares valued at approximately CAD$9,459,954.20, based on NeuroThera's 20-day volume weighted average trading price on the TSX Venture Exchange as of the share purchase agreement date.</p> <p>The transaction includes potential earn-out payments of up to $2,500,000 over three years. These payments consist of $500,000 for each of the first three patent applications filed regarding the licensed technology, up to $1,500,000 total, and 7% http://www.streetinsider.com/Mergers+and+Acquisitions/NeuroThera+Labs+acquires+54%25+stake+in+CliniQuantum+for+CAD%249.5+million/26602471.html Thu, 04 Jun 2026 07:32:19 -0400 A.36078215 O.02555813 O.06196855 SPRC http://www.streetinsider.com/Press+Releases/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html <p>TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (&quot;NeuroThera&quot;), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the closing of its acquisition of approximately 54% interest in CliniQuantum Ltd. (&quot;CliniQuantum&quot;).</p> <p>According to the share purchase agreement (the “SPA”), pursuant to which, NeuroThera acquired 56,375 ordinary shares of CliniQuatum (the “Transaction”), representing approximately 54% of the issued and outstanding ordinary shares of CliniQuantum, in consideration for the issuance of 56,600,000 common shares of NeuroThera http://www.streetinsider.com/Press+Releases/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html Thu, 04 Jun 2026 07:32:00 -0400 A.36078215 O.02555813 O.06196855 SPRC http://www.streetinsider.com/Press+Releases/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html <p>TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (&quot;NeuroThera&quot;), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the closing of its acquisition of approximately 54% interest in CliniQuantum Ltd. (&quot;CliniQuantum&quot;).</p> <p>According to the share purchase agreement (the “SPA”), pursuant to which, NeuroThera acquired 56,375 ordinary shares of CliniQuatum (the “Transaction”), representing approximately 54% of the issued and outstanding ordinary shares of CliniQuantum, in consideration for the issuance of 56,600,000 common shares of NeuroThera http://www.streetinsider.com/Press+Releases/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html Thu, 04 Jun 2026 07:32:00 -0400 A.36078215 O.02555813 O.06196855 SPRC http://www.streetinsider.com/Press+Releases/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html <p>TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (&quot;NeuroThera&quot;), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the closing of its acquisition of approximately 54% interest in CliniQuantum Ltd. (&quot;CliniQuantum&quot;).</p> <p>According to the share purchase agreement (the “SPA”), pursuant to which, NeuroThera acquired 56,375 ordinary shares of CliniQuatum (the “Transaction”), representing approximately 54% of the issued and outstanding ordinary shares of CliniQuantum, in consideration for the issuance of 56,600,000 common shares of NeuroThera http://www.streetinsider.com/Press+Releases/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html Thu, 04 Jun 2026 07:32:00 -0400 A.36078215 O.02555813 O.06196855 SPRC http://www.streetinsider.com/Press+Releases/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html <p>TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (&quot;NeuroThera&quot;), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the closing of its acquisition of approximately 54% interest in CliniQuantum Ltd. (&quot;CliniQuantum&quot;).</p> <p>According to the share purchase agreement (the “SPA”), pursuant to which, NeuroThera acquired 56,375 ordinary shares of CliniQuatum (the “Transaction”), representing approximately 54% of the issued and outstanding ordinary shares of CliniQuantum, in consideration for the issuance of 56,600,000 common shares of NeuroThera http://www.streetinsider.com/Press+Releases/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html Thu, 04 Jun 2026 07:32:00 -0400 A.36078215 O.02555813 O.06196855 SPRC http://www.streetinsider.com/Globe+Newswire/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html <p>TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (&quot;NeuroThera&quot;), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the closing of its acquisition of approximately 54% interest in CliniQuantum Ltd. (&quot;CliniQuantum&quot;).</p> <p>According to the share purchase agreement (the “SPA”), pursuant to which, NeuroThera acquired 56,375 ordinary shares of CliniQuatum (the “Transaction”), representing approximately 54% of the issued and outstanding ordinary shares of CliniQuantum, in consideration for the issuance of 56,600,000 common shares of NeuroThera http://www.streetinsider.com/Globe+Newswire/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html Thu, 04 Jun 2026 07:32:00 -0400 A.36078215 O.02555813 O.06196855 SPRC http://www.streetinsider.com/Globe+Newswire/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html <p>TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (&quot;NeuroThera&quot;), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the closing of its acquisition of approximately 54% interest in CliniQuantum Ltd. (&quot;CliniQuantum&quot;).</p> <p>According to the share purchase agreement (the “SPA”), pursuant to which, NeuroThera acquired 56,375 ordinary shares of CliniQuatum (the “Transaction”), representing approximately 54% of the issued and outstanding ordinary shares of CliniQuantum, in consideration for the issuance of 56,600,000 common shares of NeuroThera http://www.streetinsider.com/Globe+Newswire/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html Thu, 04 Jun 2026 07:32:00 -0400 A.36078215 O.02555813 O.06196855 SPRC http://www.streetinsider.com/Globe+Newswire/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html <p>TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (&quot;NeuroThera&quot;), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the closing of its acquisition of approximately 54% interest in CliniQuantum Ltd. (&quot;CliniQuantum&quot;).</p> <p>According to the share purchase agreement (the “SPA”), pursuant to which, NeuroThera acquired 56,375 ordinary shares of CliniQuatum (the “Transaction”), representing approximately 54% of the issued and outstanding ordinary shares of CliniQuantum, in consideration for the issuance of 56,600,000 common shares of NeuroThera http://www.streetinsider.com/Globe+Newswire/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html Thu, 04 Jun 2026 07:32:00 -0400 A.36078215 O.02555813 O.06196855 SPRC http://www.streetinsider.com/Globe+Newswire/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html <p>TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (&quot;NeuroThera&quot;), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the closing of its acquisition of approximately 54% interest in CliniQuantum Ltd. (&quot;CliniQuantum&quot;).</p> <p>According to the share purchase agreement (the “SPA”), pursuant to which, NeuroThera acquired 56,375 ordinary shares of CliniQuatum (the “Transaction”), representing approximately 54% of the issued and outstanding ordinary shares of CliniQuantum, in consideration for the issuance of 56,600,000 common shares of NeuroThera http://www.streetinsider.com/Globe+Newswire/SciSparc%3A+Subsidiary+NeuroThera+Labs+Completed+Acquisition+of+CliniQuantum/26602467.html Thu, 04 Jun 2026 07:32:00 -0400 A.36078215 O.02555813 O.06196855 SPRC http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SciSparc+Ltd.+++++++++++++For%3A+Jun+01++Filed+by%3A+Shrem+Itschak/26595655.html si-local-file:///var/storage/secattach/20260603/26595655.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SciSparc+Ltd.+++++++++++++For%3A+Jun+01++Filed+by%3A+Shrem+Itschak/26595655.html Wed, 03 Jun 2026 08:00:00 -0400 O.06196855 SPRC http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SciSparc+Ltd.+++++++++++++For%3A+Jun+01++Filed+by%3A+Shrem+Itschak/26595655.html si-local-file:///var/storage/secattach/20260603/26595655.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SciSparc+Ltd.+++++++++++++For%3A+Jun+01++Filed+by%3A+Shrem+Itschak/26595655.html Wed, 03 Jun 2026 08:00:00 -0400 O.06196855 SPRC http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SciSparc+Ltd.+++++++++++++For%3A+May+29/26570800.html si-local-file:///var/storage/secattach/20260529/26570800.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SciSparc+Ltd.+++++++++++++For%3A+May+29/26570800.html Fri, 29 May 2026 07:40:00 -0400 O.06196855 SPRC http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SciSparc+Ltd.+++++++++++++For%3A+May+29/26570800.html si-local-file:///var/storage/secattach/20260529/26570800.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SciSparc+Ltd.+++++++++++++For%3A+May+29/26570800.html Fri, 29 May 2026 07:40:00 -0400 O.06196855 SPRC http://www.streetinsider.com/Mergers+and+Acquisitions/NeuroThera+Labs+receives+conditional+approval+for+CliniQuantum+acquisition/26561913.html <p>NeuroThera Labs Inc. (TSXV: NTLX) received conditional regulatory approval from the TSX Venture Exchange for its acquisition of approximately 54% of CliniQuantum Ltd., according to a statement from parent company SciSparc Ltd. (NASDAQ: SPRC).</p> <p>Under the share purchase agreement signed in March 2026, NeuroThera will acquire 56,375 ordinary shares of CliniQuantum in exchange for issuing 56,600,000 common shares to CliniQuantum shareholders. The transaction is valued at approximately $9.5 million based on NeuroThera's 20-day volume weighted average trading price.</p> <p>CliniQuantum is an Israeli technology company developing a platform that uses quantum simulation and quantum Monte Carlo methods for clinical trial data analysis. The http://www.streetinsider.com/Mergers+and+Acquisitions/NeuroThera+Labs+receives+conditional+approval+for+CliniQuantum+acquisition/26561913.html Thu, 28 May 2026 08:40:16 -0400 SPRC http://www.streetinsider.com/Press+Releases/SciSparc%3A+Subsidiary+NeuroThera+Labs+Received+Conditional+Regulatory+Approval+for+Acquisition+of+CliniQuantum/26561910.html <p align="justify">TEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, received a conditional regulatory approval from the TSX Venture Exchange (“TSX”) for the acquisition of approximately 54% interest in CliniQuantum Ltd. ("CliniQuantum") (the Transaction”). </p> <p align="justify">As previously disclosed, in March 2026, NeuroThera, CliniQuantum and the certain shareholders of CliniQuantum, (the “Selling Shareholders”) entered into a share purchase agreement (the “SPA”), pursuant to which, NeuroThera will acquire 56,375 http://www.streetinsider.com/Press+Releases/SciSparc%3A+Subsidiary+NeuroThera+Labs+Received+Conditional+Regulatory+Approval+for+Acquisition+of+CliniQuantum/26561910.html Thu, 28 May 2026 08:40:00 -0400 SPRC SPRC http://www.streetinsider.com/Press+Releases/SciSparc%3A+Subsidiary+NeuroThera+Labs+Received+Conditional+Regulatory+Approval+for+Acquisition+of+CliniQuantum/26561910.html <p align="justify">TEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, received a conditional regulatory approval from the TSX Venture Exchange (“TSX”) for the acquisition of approximately 54% interest in CliniQuantum Ltd. ("CliniQuantum") (the Transaction”). </p> <p align="justify">As previously disclosed, in March 2026, NeuroThera, CliniQuantum and the certain shareholders of CliniQuantum, (the “Selling Shareholders”) entered into a share purchase agreement (the “SPA”), pursuant to which, NeuroThera will acquire 56,375 http://www.streetinsider.com/Press+Releases/SciSparc%3A+Subsidiary+NeuroThera+Labs+Received+Conditional+Regulatory+Approval+for+Acquisition+of+CliniQuantum/26561910.html Thu, 28 May 2026 08:40:00 -0400 SPRC SPRC http://www.streetinsider.com/Globe+Newswire/SciSparc%3A+Subsidiary+NeuroThera+Labs+Received+Conditional+Regulatory+Approval+for+Acquisition+of+CliniQuantum/26561910.html <p align="justify">TEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, received a conditional regulatory approval from the TSX Venture Exchange (“TSX”) for the acquisition of approximately 54% interest in CliniQuantum Ltd. ("CliniQuantum") (the Transaction”). </p> <p align="justify">As previously disclosed, in March 2026, NeuroThera, CliniQuantum and the certain shareholders of CliniQuantum, (the “Selling Shareholders”) entered into a share purchase agreement (the “SPA”), pursuant to which, NeuroThera will acquire 56,375 http://www.streetinsider.com/Globe+Newswire/SciSparc%3A+Subsidiary+NeuroThera+Labs+Received+Conditional+Regulatory+Approval+for+Acquisition+of+CliniQuantum/26561910.html Thu, 28 May 2026 08:40:00 -0400 SPRC SPRC http://www.streetinsider.com/Globe+Newswire/SciSparc%3A+Subsidiary+NeuroThera+Labs+Received+Conditional+Regulatory+Approval+for+Acquisition+of+CliniQuantum/26561910.html <p align="justify">TEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, received a conditional regulatory approval from the TSX Venture Exchange (“TSX”) for the acquisition of approximately 54% interest in CliniQuantum Ltd. ("CliniQuantum") (the Transaction”). </p> <p align="justify">As previously disclosed, in March 2026, NeuroThera, CliniQuantum and the certain shareholders of CliniQuantum, (the “Selling Shareholders”) entered into a share purchase agreement (the “SPA”), pursuant to which, NeuroThera will acquire 56,375 http://www.streetinsider.com/Globe+Newswire/SciSparc%3A+Subsidiary+NeuroThera+Labs+Received+Conditional+Regulatory+Approval+for+Acquisition+of+CliniQuantum/26561910.html Thu, 28 May 2026 08:40:00 -0400 SPRC SPRC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SciSparc+Ltd.++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26506044.html si-local-file:///var/storage/secattach/20260515/26506044.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SciSparc+Ltd.++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26506044.html Fri, 15 May 2026 16:26:00 -0400 O.06196855 SPRC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SciSparc+Ltd.++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26506044.html si-local-file:///var/storage/secattach/20260515/26506044.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SciSparc+Ltd.++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26506044.html Fri, 15 May 2026 16:26:00 -0400 O.06196855 SPRC